Radiation & Double-Drug combo tested to keep advanced kidney cancer at bay
NCT ID NCT07223541
Summary
This study is testing whether adding a second immunotherapy drug (fianlimab) to a standard one (cemiplimab) works better to control cancer after precise radiation treatment. It involves 72 adults with clear cell kidney cancer that has spread to only a few other sites in the body. Participants receive radiation first, then are randomly assigned to get either the single drug or the two-drug combination for up to one year to see which keeps the cancer from growing longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.